Biomarkers in lung cancer: Present status and future perspective -what is a useful biomarker for lung cancer?

Research output: Contribution to journalArticle

Abstract

Biomarkers have been defined as having a characteristic that is objectively measurable and evaluable as an indicator of normal biologic processes, pathogenic process, or pharmacologic response to a therapeutic intervention. In most instances, they are proteins or their fragments, DNA and RNA, low molecular compounds. In lung cancer, molecular markers are expected to play roles in early detection and screening, in anticipation of a therapeutic response and outcome (prognosis), and the safety of the treatment. Future clinical trials are closely associated with the prognosis and response to the treatment.

Original languageEnglish
Pages (from-to)87-91
Number of pages5
JournalBiotherapy
Volume23
Issue number2
Publication statusPublished - 2009 Mar
Externally publishedYes

Fingerprint

Lung Neoplasms
Biomarkers
Clinical Trials
RNA
Safety
DNA
Therapeutics
Proteins
Pharmacological Phenomena

Keywords

  • Biomarker
  • CEA
  • Lung cancer
  • Tumor marker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biomarkers in lung cancer : Present status and future perspective -what is a useful biomarker for lung cancer? / Asamura, Hisao.

In: Biotherapy, Vol. 23, No. 2, 03.2009, p. 87-91.

Research output: Contribution to journalArticle

@article{1d11521138564584bf6538e0190576a3,
title = "Biomarkers in lung cancer: Present status and future perspective -what is a useful biomarker for lung cancer?",
abstract = "Biomarkers have been defined as having a characteristic that is objectively measurable and evaluable as an indicator of normal biologic processes, pathogenic process, or pharmacologic response to a therapeutic intervention. In most instances, they are proteins or their fragments, DNA and RNA, low molecular compounds. In lung cancer, molecular markers are expected to play roles in early detection and screening, in anticipation of a therapeutic response and outcome (prognosis), and the safety of the treatment. Future clinical trials are closely associated with the prognosis and response to the treatment.",
keywords = "Biomarker, CEA, Lung cancer, Tumor marker",
author = "Hisao Asamura",
year = "2009",
month = "3",
language = "English",
volume = "23",
pages = "87--91",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "2",

}

TY - JOUR

T1 - Biomarkers in lung cancer

T2 - Present status and future perspective -what is a useful biomarker for lung cancer?

AU - Asamura, Hisao

PY - 2009/3

Y1 - 2009/3

N2 - Biomarkers have been defined as having a characteristic that is objectively measurable and evaluable as an indicator of normal biologic processes, pathogenic process, or pharmacologic response to a therapeutic intervention. In most instances, they are proteins or their fragments, DNA and RNA, low molecular compounds. In lung cancer, molecular markers are expected to play roles in early detection and screening, in anticipation of a therapeutic response and outcome (prognosis), and the safety of the treatment. Future clinical trials are closely associated with the prognosis and response to the treatment.

AB - Biomarkers have been defined as having a characteristic that is objectively measurable and evaluable as an indicator of normal biologic processes, pathogenic process, or pharmacologic response to a therapeutic intervention. In most instances, they are proteins or their fragments, DNA and RNA, low molecular compounds. In lung cancer, molecular markers are expected to play roles in early detection and screening, in anticipation of a therapeutic response and outcome (prognosis), and the safety of the treatment. Future clinical trials are closely associated with the prognosis and response to the treatment.

KW - Biomarker

KW - CEA

KW - Lung cancer

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=64849098474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64849098474&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:64849098474

VL - 23

SP - 87

EP - 91

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 2

ER -